Table 1.
Ongoing therapy | Number of patients | Percentage of patients |
---|---|---|
Ustekinumab | 61 | 25% |
Etanercept | 55 | 22% |
Secukinumab | 37 | 15% |
Adalimumab | 36 | 15% |
Apremilast | 22 | 9% |
Ixekizumab | 14 | 6% |
Guselkumab | 10 | 4% |
Risankizumab | 6 | 3% |
Infliximab | 3 | 1% |
Brodalumab | 1 | 0% |
Certolizumab | 1 | 0% |